Dr Michael Northend details
Telephone:
Email:
Location:
- University College Hospital Macmillan Cancer Centre
GMC/GDC number:
7169820
Professional background
Dr Michael Northend is a haematologist specialising in the treamtent of all forms of lymphoma and the delivery of CAR T-cell therapy and other cellular immunotherapies. He is actively involved in clinical trials in these areas.
He graduated from UCL Medical School in 2011 and subsequently completed higher specialty training in haematology at UCLH and other North Central London hospitals. During his specialty training he completed a clinical research fellowship at the Cancer Research UK and UCL Cancer Trials Centre where he worked on the development, delivery and reporting of a number of clinical trials in lymphoma.
He was appointed consultant haematologist at UCLH in 2024 where he is a clinical trial site principle investigator and also education and training lead for resident doctors working in the UCLH haematology team.
Specialties
Research interests
- Cellular immunotherapies
- Lymphoma
- Clinical trials
- Late effects of treatment
Publications
- Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial. Northend M, Wilson W, Ediriwickrema K, Clifton-Hadley L… Linch DC, Ardeshna KM et al. Lancet Haematol. 2025 May;12(5):e335-e345.
- International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Binkley MS, Flerlage, Hoppe RT, Northend M, GLOW consortium collaborators et al. J Clin Oncol. 2024. 2024. Jul. 1;42(19):2271-2280
- Results of a UK real world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory large B-cell lymphoma. Northend M, Wilson W, Osborne W, Fox CP, Davies AJ… Townsend W. Blood Advances. 2022. May 10;6(9):2920-2926.
- Non-Hodgkin lymphoma. Northend M, Lambert J. Medicine. 2021, 49(5):293-300.
- Novel Therapy Approaches to Follicular Lymphoma. Northend M, Townsend W. Drugs. 2021; 81(4):453-469.